DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/18ede8/diabetic_nephropat) has announced the addition of GlobalData's new report "Diabetic Nephropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.
The report is an essential source of information and analysis on the global Diabetic Nephropathy Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Nephropathy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Nephropathy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Diabetic Nephropathy Therapeutics Market Forecast to Display Modest Growth until 2017
GlobalData estimates that the global diabetic nephropathy (DN) therapeutics market valued $1.65 billion in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 7.6% during 2005-2010. However, during 2010-2017, the market is expected to record a CAGR of 5.2%, to reach $2.35 billion by 2017. This lower CAGR is primarily attributed to the patent expiration of marketed drugs: the Cozaar patent expiration in November 2011, the Avapro patent expiration in September 2011 and the Diovan patent expiration in March 2012. Other significant factors contributing to the decreased CAGR include the asymptomatic nature of the disease, often diagnosed at later stage, the increased use of generic and off-label drugs. In addition, although disease awareness is high, patient compliance with drugs and diet regimen is low. The current competitive landscape consists of branded, generic and off-label drugs.
Changing Future Landscape of the Diabetic Nephropathy Market
GlobalData expects Reata Pharmaceuticals, Inc., Glycadia Pharmaceuticals, Inc., Angelini Group, NephroGenex Inc., Eli Lilly, Abbott Laboratories, FibroGen, Inc. and Torrent Pharmaceuticals Limited to be key companies in this market in the future. GlobalData holds profiles of all of the above companies as they possess important pipeline drugs in early and late stage development for DN therapeutics.
The existing market landscape remains competitive because the treatment of DN relies on older, more established therapies such as angiotensin-converting enzyme (ACE) inhibitors, ARBs (angiotensin receptor blockers), and calcium channel blockers (CCBs), diuretics and beta blockers. The market scenario will change following the launch of new disease modifying therapies such as ACEs inhibitor, antioxidant inflammation modulator, connective tissue growth factor (CTGF) Inhibitor, monocyte chemoattractant proteins (MCP) inhibitor, selective glycation inhibitor, transforming growth factor beta regulator, selective Endothelin-A Receptor (ETAR) antagonist, urotensin II receptor antagonist, IL-12 inhibitors and STAT-4 activator, Nox4 inhibitor, G protein-coupled receptors (GPCRs) antagonist, and erythropoiesis stimulating agent.
The report provides information on the key drivers and challenges of the Diabetic Nephropathy Therapeutics market. Its scope includes:
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Nephropathy Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Diabetic Nephropathy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Companies Mentioned:
- Reata Pharmaceuticals, Inc.
- Eli Lilly and Company
- Abbott Laboratories
- Pfizer
- Sanofi-Aventis
For more information visit http://www.researchandmarkets.com/research/18ede8/diabetic_nephropat.